Effects of dapagliflozin in type 2 diabetes and heart failure with mildly reduced or preserved ejection fraction across the background of glucose-lowering therapy in DELIVER
In this medfyle
In patients with T2D with HFmrEF/HFpEF, dapagliflozin has consistent benefit across most types and numbers of concurrent anti-hyperglycemic therapies.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
This is a summary of a presentation given at the EASD 2023 Annual Meeting. The content is developed by Infomedica in collaboration with the Diabetes Education Study Group (DESG).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the DESG.
©2023 Infomedica-Medfyle. All rights reserved.
